These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 17611561)

  • 21. HS1 protein is differentially expressed in chronic lymphocytic leukemia patient subsets with good or poor prognoses.
    Scielzo C; Ghia P; Conti A; Bachi A; Guida G; Geuna M; Alessio M; Caligaris-Cappio F
    J Clin Invest; 2005 Jun; 115(6):1644-50. PubMed ID: 15931393
    [TBL] [Abstract][Full Text] [Related]  

  • 22. p65 activity and ZAP-70 status predict the sensitivity of chronic lymphocytic leukemia cells to the selective IkappaB kinase inhibitor BMS-345541.
    López-Guerra M; Roué G; Pérez-Galán P; Alonso R; Villamor N; Montserrat E; Campo E; Colomer D
    Clin Cancer Res; 2009 Apr; 15(8):2767-76. PubMed ID: 19351760
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Integrated genomic profiling of chronic lymphocytic leukemia identifies subtypes of deletion 13q14.
    Ouillette P; Erba H; Kujawski L; Kaminski M; Shedden K; Malek SN
    Cancer Res; 2008 Feb; 68(4):1012-21. PubMed ID: 18281475
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Defining the prognosis of early stage chronic lymphocytic leukaemia patients.
    Pepper C; Majid A; Lin TT; Hewamana S; Pratt G; Walewska R; Gesk S; Siebert R; Wagner S; Kennedy B; Miall F; Davis ZA; Tracy I; Gardiner AC; Brennan P; Hills RK; Dyer MJ; Oscier D; Fegan C
    Br J Haematol; 2012 Feb; 156(4):499-507. PubMed ID: 22171799
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Highly purified CD38+ and CD38- sub-clones derived from the same chronic lymphocytic leukemia patient have distinct gene expression signatures despite their monoclonal origin.
    Pepper C; Ward R; Lin TT; Brennan P; Starczynski J; Musson M; Rowntree C; Bentley P; Mills K; Pratt G; Fegan C
    Leukemia; 2007 Apr; 21(4):687-96. PubMed ID: 17287849
    [TBL] [Abstract][Full Text] [Related]  

  • 26. IGHV3-21 gene usage is associated with high TCL1 expression in chronic lymphocytic leukemia.
    Mansouri MR; Sevov M; Aleskog A; Jondal M; Merup M; Sundström C; Osorio L; Rosenquist R
    Eur J Haematol; 2010 Feb; 84(2):109-16. PubMed ID: 19889012
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of the RANKL/RANK system in the induction of interleukin-8 (IL-8) in B chronic lymphocytic leukemia (B-CLL) cells.
    Secchiero P; Corallini F; Barbarotto E; Melloni E; di Iasio MG; Tiribelli M; Zauli G
    J Cell Physiol; 2006 Apr; 207(1):158-64. PubMed ID: 16270354
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of gene expression signatures for molecular classification in human leukemia cells.
    Song JH; Kim HJ; Lee CH; Kim SJ; Hwang SY; Kim TS
    Int J Oncol; 2006 Jul; 29(1):57-64. PubMed ID: 16773185
    [TBL] [Abstract][Full Text] [Related]  

  • 29. B-chronic lymphocytic leukemia cells contain both endogenous kappa immunoglobulin mRNA and critical immunoglobulin gene activation transcription factors.
    Zaknoen SL; Christian SL; Suen R; Van Ness B; Kay NE
    Leukemia; 1992 Jul; 6(7):675-9. PubMed ID: 1625486
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PTPROt-mediated regulation of p53/Foxm1 suppresses leukemic phenotype in a CLL mouse model.
    Motiwala T; Kutay H; Zanesi N; Frissora FW; Mo X; Muthusamy N; Jacob ST
    Leukemia; 2015 Jun; 29(6):1350-9. PubMed ID: 25482129
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunocytochemical detection of bcl-2 and p53 proteins in B-chronic lymphocytic leukemia patients.
    Klobusická M; Kusenda J; Babusíková O
    Neoplasma; 2002; 49(6):387-93. PubMed ID: 12584586
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dendrimer-based nanoparticles for potential personalized therapy in chronic lymphocytic leukemia: Targeting the BCR-signaling pathway.
    Franiak-Pietryga I; Maciejewski H; Ostrowska K; Appelhans D; Voit B; Misiewicz M; Kowalczyk P; Bryszewska M; Borowiec M
    Int J Biol Macromol; 2016 Jul; 88():156-61. PubMed ID: 26987432
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetic lesions in chronic lymphocytic leukemia: clinical implications.
    Montserrat E; Moreno C
    Curr Opin Oncol; 2009 Nov; 21(6):609-14. PubMed ID: 19713841
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The regulatory interaction of EVI1 with the TCL1A oncogene impacts cell survival and clinical outcome in CLL.
    Vasyutina E; Boucas JM; Bloehdorn J; Aszyk C; Crispatzu G; Stiefelhagen M; Breuer A; Mayer P; Lengerke C; Döhner H; Beutner D; Rosenwald A; Stilgenbauer S; Hallek M; Benner A; Herling M
    Leukemia; 2015 Oct; 29(10):2003-14. PubMed ID: 25936528
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Protein kinase D-dependent CXCR4 down-regulation upon BCR triggering is linked to lymphadenopathy in chronic lymphocytic leukaemia.
    Saint-Georges S; Quettier M; Bouyaba M; Le Coquil S; Laurienté V; Guittat L; Lévy V; Ajchenbaum-Cymbalista F; Varin-Blank N; Le Roy C; Ledoux D
    Oncotarget; 2016 Jul; 7(27):41031-41046. PubMed ID: 27127886
    [TBL] [Abstract][Full Text] [Related]  

  • 36. miR-29 modulates CD40 signaling in chronic lymphocytic leukemia by targeting TRAF4: an axis affected by BCR inhibitors.
    Sharma S; Pavlasova GM; Seda V; Cerna KA; Vojackova E; Filip D; Ondrisova L; Sandova V; Kostalova L; Zeni PF; Borsky M; Oppelt J; Liskova K; Kren L; Janikova A; Pospisilova S; Fernandes SM; Shehata M; Rassenti LZ; Jaeger U; Doubek M; Davids MS; Brown JR; Mayer J; Kipps TJ; Mraz M
    Blood; 2021 May; 137(18):2481-2494. PubMed ID: 33171493
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sprouty 2: a novel attenuator of B-cell receptor and MAPK-Erk signaling in CLL.
    Shukla A; Rai K; Shukla V; Chaturvedi NK; Bociek RG; Pirruccello SJ; Band H; Lu R; Joshi SS
    Blood; 2016 May; 127(19):2310-21. PubMed ID: 26809508
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The novel antisense Bcl-2 inhibitor SPC2996 causes rapid leukemic cell clearance and immune activation in chronic lymphocytic leukemia.
    Dürig J; Dührsen U; Klein-Hitpass L; Worm J; Hansen JB; Ørum H; Wissenbach M
    Leukemia; 2011 Apr; 25(4):638-47. PubMed ID: 21358717
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Expression of Toll-Like Receptors in Patients with B-Cell Chronic Lymphocytic Leukemia.
    Rybka J; Butrym A; Wróbel T; Jaźwiec B; Bogucka-Fedorczuk A; Poręba R; Kuliczkowski K
    Arch Immunol Ther Exp (Warsz); 2016 Dec; 64(Suppl 1):147-150. PubMed ID: 28083607
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Variability in the degree of expression of phosphorylated IkappaBalpha in chronic lymphocytic leukemia cases with nodal involvement.
    Rodríguez A; Martínez N; Camacho FI; Ruíz-Ballesteros E; Algara P; García JF; Menárguez J; Alvaro T; Fresno MF; Solano F; Mollejo M; Martin C; Piris MA
    Clin Cancer Res; 2004 Oct; 10(20):6796-806. PubMed ID: 15501956
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.